Compare Pfizer Inc (PFE) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

VOO, the Vanguard S&P 500 ETF, trades at $682.20, down slightly by 0.14% over 24 hours. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF recently surpassed $1.0 trillion in assets under management, reflecting strong institutional confidence. A dividend of $1.96 is scheduled for payment on June 30, 2026.

The outlook for VOO is mixed; its low-cost, diversified exposure to the S&P 500 offers long-term growth potential, but current technical weakness and elevated market valuations pose near-term risks. Investors should weigh the ETF's historical resilience against potential volatility from economic shifts or sector rotations.